BRNS vs. KYTX, PBYI, RENB, OGI, PRQR, JMAC, HRTX, VOR, ENTA, and SGMT
Should you be buying Barinthus Biotherapeutics stock or one of its competitors? The main competitors of Barinthus Biotherapeutics include Kyverna Therapeutics (KYTX), Puma Biotechnology (PBYI), Lunai Bioworks (RENB), Organigram Global (OGI), ProQR Therapeutics (PRQR), Maxpro Capital Acquisition (JMAC), Heron Therapeutics (HRTX), Vor Biopharma (VOR), Enanta Pharmaceuticals (ENTA), and Sagimet Biosciences (SGMT). These companies are all part of the "pharmaceutical products" industry.
Barinthus Biotherapeutics vs. Its Competitors
Barinthus Biotherapeutics (NASDAQ:BRNS) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.
Barinthus Biotherapeutics has higher revenue and earnings than Kyverna Therapeutics. Kyverna Therapeutics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Kyverna Therapeutics had 2 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 5 mentions for Kyverna Therapeutics and 3 mentions for Barinthus Biotherapeutics. Barinthus Biotherapeutics' average media sentiment score of 0.95 beat Kyverna Therapeutics' score of 0.56 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media.
Barinthus Biotherapeutics has a beta of -0.71, indicating that its share price is 171% less volatile than the S&P 500. Comparatively, Kyverna Therapeutics has a beta of 3.72, indicating that its share price is 272% more volatile than the S&P 500.
Barinthus Biotherapeutics currently has a consensus price target of $3.00, indicating a potential upside of 120.59%. Kyverna Therapeutics has a consensus price target of $19.00, indicating a potential upside of 181.07%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kyverna Therapeutics is more favorable than Barinthus Biotherapeutics.
Barinthus Biotherapeutics' return on equity of -54.70% beat Kyverna Therapeutics' return on equity.
25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are held by institutional investors. 8.0% of Barinthus Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Barinthus Biotherapeutics beats Kyverna Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Barinthus Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Barinthus Biotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BRNS) was last updated on 10/14/2025 by MarketBeat.com Staff
